Myeloid-derived suppressor cells (MDSC) are an immunosuppressive population of immature myeloid cells found in advanced-stage cancer patients and mouse tumor models. Production of inducible nitric oxide synthase (iNOS) and arginase, as well as other suppressive mechanisms, allows MDSCs to suppress T-cell-mediated tumor clearance and foster tumor progression. Using an unbiased global gene expression approach in conditional p120-catenin knockout mice (L2-cre;p120ctn
Introduction
The immune system (both innate and adaptive) plays an essential role in limiting tumor growth and, therefore, tumor progression requires escape from immune surveillance. One mechanism that allows for tumor escape is the activation and expansion of immunosuppressive cell populations, including, but not limited to, regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC; ref. 1) , the latter also referred to as immature myeloid cells. Certain therapeutics have demonstrated potential efficacy against MDSCs (2); however, the need for more selective anti-MDSC therapeutics remains.
MDSCs have been observed in a number of mouse tumor models and represent a heterogeneous population of immature monocytes and granulocytes that are identified by their CD11b þ Gr-1 þ phenotype in mice (3) . In human disease, the first immature myeloid cell population with immunosuppressive capacity was described in head and neck cancer (4) , and since then MDSCs have been documented in cancers of the esophagus, stomach, pancreas, lung, kidney, colon, skin, prostate, and breast (5) (6) (7) (8) (9) (10) . The immunophenotype of human MDSCs varies (11) ; however, their immunosuppressive mechanisms match those found in murine CD11b
MDSCs induce immune suppression primarily through inhibition of T-cell-mediated tumor clearance (3), but can also promote inhibition of NK cells (12) and activation of Tregs (13) . Arginase-1 and inducible nitric oxide synthase-2 (iNOS) provide the bulk of enzymatic activity required for MDSCs to suppress T-cell proliferation and activation (3) . Arginase-1 deprives T cells of arginine by converting it into urea and Lornithine, thereby reducing expression of CD3z chain, which renders T cells unable to respond to activation signals (14) . iNOS inhibits T-cell function by a variety of mechanisms, including inhibition of JAK3/STAT5 signaling (15) , MHC Class II expression (16) , and induction of apoptosis (17) .
CD38 expression is a common characteristic to several immunosuppressive cell types. Foxp3
þ CD4 þ Tregs expressing high CD38 levels possess a greater immunosuppressive activity than CD38 low Tregs (18) . CD38 þ CD8 þ T cells suppress proliferation of CD4 þ effector T cells, which requires IFNg secretion and cell-to-cell contact (19) . Similarly, CD19 þ CD24 high CD38 high B cells inhibit differentiation of Th1 cells in an IL10-dependent manner, and their dysfunction may play a role in autoimmune disorders such as systemic lupus erythematosus (20) .
CD38 is a member of the ribosyl cyclase family and is expressed on the surface of diverse immune cells, including B cells, T cells, NK cells, and myeloid cells (21) . CD38 possesses independent ectoenzyme and receptor functions. As an ectozyme, CD38 catalyzes synthesis and hydrolysis of cyclic ADP-ribose (cADPR), converting NAD þ to ADP-ribose (ADPR), as well as cADPR into ADPR (21, 22) . Furthermore, at acidic pH, CD38 catalyzes synthesis and hydrolysis of nicotinic acid adenine dinucleotide phosphate (NAADP; refs. 21, 22) . Both reactions are essential for calcium signaling, specifically for mobilization of intracellular Ca 2þ (22) . Receptor activity of CD38 has been documented in multiple immune cell types, where it is dependent on localization to the lipid rafts and association with professional signaling complexes (21) . In both mouse and human myeloid cells, ligation of CD38 receptor leads to suppressed growth and survival, resulting in loss of the most differentiated immune populations (23) .
In this study, we have identified CD38 as a novel marker for MDSCs that possess greater immunosuppressive capacity, thereby promoting tumor growth in vivo. We have identified a mechanistic role for CD38 in promoting expansion of the monocytic MDSC population, as well as in regulating expression of the effector molecule iNOS by these cells. In addition, we have established for the first time that several cytokines, specifically IFNg, TNFa, IGFBP3, CXCL16, and IL6, are capable of inducing CD38 expression in MDSCs. Finally, we have demonstrated that administration of an anti-CD38 monoclonal antibody slows disease progression in tumor-bearing mice. As we have detected an expansion of CD38-positive MDSC-like population in peripheral blood of advanced-stage cancer patients, this study introduces the concept of anti-CD38 monoclonal antibody therapy for potential treatment of certain solid tumors.
Materials and Methods

Cell lines
AKR and HNM007 mouse esophageal squamous cell carcinoma (ESCC) tumor lines have been described previously (25, 26) . Cells were maintained in DMEM þ 10% FBS and passaged or harvested at approximately 80% confluency. We have propagated cells from frozen stocks of the original vials that were authenticated by short tandem repeat analysis for highly polymorphic microsatellites FES/FPS, vWA31, D22S417, D10S526, and D5S592 so as to validate the identity of cells by comparing cells from the earliest stocks and those grown more than 8 to 12 passages. All cell lines have been tested for mycoplasma contamination on a regular basis.
Generation of MDSCs
All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania (Philadelphia, PA). The L2-Cre;p120ctn
f/f mouse model of oralesophageal cancer developed by us was described previously (24) . The mouse ESCC tumor lines have been described previously (25, 26) . A total of 2.5Â10 5 AKR or HNM007 cells/ animal were injected subcutaneously into C57BL/6J or Cd38 À/À mice (gift from Dr. Eduardo Chini, Department of Anesthesia, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN). Subcutaneous tumor-bearing mice were aged until tumors reached a volume of 0.8 cm 3 . Spleens and bone marrow were harvested upon euthanasia for MDSC isolation.
FACS
Single-cell suspensions were prepared from mouse bone marrow or spleen by mechanical disruption. For NFkB and iNOS staining, cells were fixed (BD Cytofix) and permeabilized with methanol. Peripheral blood from previously untreated, advanced-stage head and neck cancer (HNC) patients was obtained with informed consent under University of Pennsylvania Institutional Review Board protocol #417200 or Philadelphia VA Medical Center protocol #01090. Patients' peripheral blood mononuclear cells (PBMC) were separated using gradient centrifugation.
T-cell suppression
CD11b
low , and CD11b
high cell populations were sorted by FACS. Antigen-specific CD8 þ T-cell suppression was tested as described previously (24) . OVA-peptide was used to stimulate proliferation of OT-1 T cells.
RNA microarray and qPCR RNA was isolated from FACS-sorted MDSCs to perform microarray (GeneChip Mouse Exon 1.0 ST Array, Affymetrix). Ingenuity Pathway Analysis software was used for data analysis. cDNA was generated using oligo-dT primers and Superscript II Reverse Transcriptase. qPCR was performed using validated SYBR Green primers and ABI7000 (Applied Biosystems).
Ex vivo MDSC differentiation
Generation of MDSCs from bone marrow has been described previously (27) . Cytokine concentrations used: 0.1 ng/mL (GM-CSF and IL4), 10 ng/mL (TNFa and IFNg), and 100 ng/mL (IL6, CXCL16, and IGFBP3). HNM007 or AKR-conditioned media (CM) were used at 50% v/v. Anti-CD38 or IgG2a isotype control antibodies were used at 10 mg/mL.
Colony formation and cell recovery assays
Isolation of MDSCs from tumor-bearing L2-cre;p120 À/À mice by magnetic cell sorting was described previously (24) . A total of 200,000 cells were cultured in MethoCult medium (Stem Cell Technologies). Anti-CD38 or IgG2a isotype control antibodies were used at 10 mg/mL. Colonies were counted after 7 days. For recovery assays, 5 Â 10 5 MDSCs were seeded in complete RPMI1640 medium supplemented with antibodies; cells were quantified by Trypan Blue exclusion using a Countess automated cell counter (Invitrogen).
Cytokine array
Media from ex vivo differentiation cultures were collected and snap-frozen after 1 or 5 days of culture. Mouse cytokine array C3 kit (Raybiotech) was used according to the manufacturer's protocol. Results were quantified using the ImageJ protein array analyzer and normalized to positive controls. 
Histology
Subcutaneous tumors were fixed in buffered formalin solution, paraffin-embedded, and stained with hematoxylin and eosin (H&E). Antigen-specific staining was performed as described previously (24) .
Statistical analysis
The Student t test was used to determine whether there is significant difference between two experimental groups (P 0.05 was considered statistically significant).
Additional details (qPCR primers, antibodies, and detailed ex vivo differentiation protocol) can be found in Supplementary Materials and Methods.
Results
MDSCs from tumor-bearing L2-Cre;p120 f/f mice exhibit elevated CD38 expression
We have previously demonstrated that MDSCs play a fundamental role in tumor initiation and progression in a spontaneous genetic mouse model of ESCC (L2-Cre;p120 f/f ; referred to hereafter as p120 À/À ; ref. 24 ). Here we sought to identify genes associated with an immature myeloid phenotype that contribute to the tumor-promoting activities of MDSCs, thereby providing a platform to elucidate underlying molecular mechanisms. To that end, we performed microarray analysis of splenic MDSCs from 6-to 8-month-old tumor-bearing p120 À/À mice and age-matched littermate controls (Supplementary Fig. S1 ; GEO accession number GSE71706). Among the 964 genes showing differential expression between the two groups ( Fig. 1A) , we identified Cd38 (ranked fifth highest among all genes tested; Supplementary Table S1) as a candidate gene of interest, as it has roles in both innate and adaptive immunity in mice and humans, including, but not limited to, chemotaxis of murine and human neutrophils (28, 29) , early myeloid differentiation (23) , and lymphoid cell activation (30) . We validated Cd38 mRNA and protein expression in MDSCs from tumor-bearing mice, compared with those isolated from control mice ( Fig. 1B-D) . We also observed increased CD38 in splenic MDSCs isolated from L2-IL1b mice, a model of Barrett esophagus and esophageal adenocarcinoma (Supplementary Fig. S2 ; ref. 31 ).
CD38 expression correlates with ESCC progression and expansion of monocytic MDSC population
To determine the kinetics of CD38 expression in MDSCs, we analyzed splenic CD11b þ Gr-1 þ populations from non-diseased expansion of myeloid populations in spleens of tumor-bearing mice, it was significantly more pronounced (P ¼ 0.0009) in HNM007 tumor-bearing mice (Fig. 2D) . Furthermore, we observed differences in distribution of granulocytic and monocytic MDSCs (G-MDSC and M-MDSC, respectively), as well as mature monocytes (Fig. 2D) . G-MDSCs (CD11b , and tumorbearing (TB) p120 À/À mice were analyzed by FACS for CD38 expression on myeloid cell populations. B, histograms comparing CD38-FITC fluorescence levels on two cell subsets from control, p120 À/À nondiseased, and p120 À/À tumor-bearing mice. C, splenocytes from control nondiseased and AKR or HNM007 subcutaneous tumor-bearing C57BL/6 mice analyzed by FACS. Histograms compare CD38 expression levels in listed subpopulations from control and tumor-bearing mice. D, splenocytes from control and tumor-bearing mice were analyzed by FACS for distribution of CD11b, Ly-6C, Ly-6G, and CD38 antigens. Pie charts demonstrate the frequencies of lymphoid (CD11b high MDSCs demonstrated significantly greater T-cell suppressive capacity, compared with their CD38 low counterparts (Fig. 3A) , at 2:1 OT-1 to MDSC ratio, while a trend of increased suppression was observed at 1:1 and 4:1 ratios.
Next, we evaluated the impact of coinjection of CD38
high MDSCs with HNM007 cells on tumor growth. Tumor volumes in CD38 high group were significantly larger than CD38 low tumors on days 6 and 10 ( Fig. 3B) , and larger than control HNM007 tumors on days 8, 10, and 13 ( Fig. 3B) . No difference in size was detected between the CD38 low and control HNM007 tumors. Furthermore, we found morphologic differences between the tumors from different experimental groups. CD38
high -injected tumors were characterized by increased necrosis, inflammatory infiltrate (mostly by MPO þ neutrophils), and reduced number of CD3 þ T cells (including CD8 þ cytotoxic T cells), compared with controls ( Fig. 3C and Supplementary Fig. S4) . S5 ; GEO accession number GSE71706) and detected differential expression of 498 genes ( Fig. 4A ; Supplementary Table S2) .
Among genes with the greatest increase in expression was inducible nitric oxide synthase (iNos). qPCR analysis further revealed that iNos expression was significantly elevated in CD38
high MDSCs compared with CD38 low MDSCs, while expression of arginase 1 (Arg1) and NADPH oxidase subunit (Nox2), two additional mediators of MDSC suppressive function, was comparable in these subpopulations (Fig. 4B) . iNOS protein expression was also validated in CD38
high MDSCs (Fig 4C and Supplementary Fig. S5B ). As iNos is a target of NFkB transactivation (32), we evaluated the levels of total and phosphorylated NFkB in CD38 high and CD38 low MDSCs and found increased phosphoNFkB-to-totalNFkB ratio in the CD38 high population (Fig.  4C and Supplementary Fig. S5B ). To test whether iNOS contributes to the increased immunosuppressive capacity of CD38 high MDSCs, we used an iNOS inhibitor (L-NMMA), and found that it completely abrogated OT-1 T-cell suppression mediated by CD38 high MDSCs (Fig. 4D) . Finally, the CD38 inhibitor AraF-NAD (33) partially rescued OT-1 T-cell proliferation (Fig. 4E) , suggesting that CD38 enzymatic activity is required for immunosuppressive capacity of CD38 high MDSCs. Furthermore, iNOS expression was decreased in MDSCs isolated from the spleens of HNM007 tumor-bearing Cd38 À/À mice ( Fig. 4F and Supplementary Fig. S5C ). Morphologic assessment of sorted CD38 low and CD38 high MDSCs revealed that the CD38 high population consists of more immature cells, such as promyelocytes ($10%), myelocytes (5%-10%), metamyeloctyes (5%-10%), and band cells ($70%), whereas the CD38 low population consists of band cells (<10%), and mature neutrophils (>90%; Fig. 4G ), demonstrating that CD38 high MDSCs are morphologically more immature than CD38 low MDSCs.
IFNg, TNFa, CXCL16, IGFBP3, and IL6 induce CD38 expression Since we found that MDSCs from HNM007 tumor-bearing mice have increased CD38 expression, compared with AKR tumors (Fig. 2C) , we sought to understand signaling pathways underlying this phenotype. We performed ex vivo bone marrow differentiation assays using GM-CSF, IL4 (both required for CD11b þ Gr-1 þ cell generation from bone marrow progenitors;
ref. 27 ) and conditioned media (CM) from either HNM007 or AKR cells. Only HNM007 CM induced CD38 expression (Fig. 5A) . As IFNg and TNFa are key components of the proinflammatory milieu and are known activators of CD38 transcription (21), we used these cytokines in ex vivo differentiation assays. Interestingly, both factors, individually or in combination, induced CD38 expression in CD11b þ Gr-1 þ cells (Fig. 5A) . A cytokine array using CM from ex vivo differentiation experiments revealed several factors, including CXCL16 and IGFBP-3 that were present at higher levels in HNM007 cultures as compared with AKR cultures (Fig. 5B ). In addition, the proinflammatory cytokine IL6, a predicted activator of CD38 transcription (21) , was elevated in HNM007 cultures, albeit not as dramatically as CXCL16 or IGFBP-3 (Fig. 5B) . Next, we investigated the capacity of recombinant IL6, CXCL16, and IGFBP3 to increase CD38 expression ex vivo. Interestingly, addition of IL6, CXCL16, and IGFBP3 in combination induced a moderate, yet significant, increase in CD38 expression in AKR CM cultures (Fig. 5C ).
Cross-linking of CD38 by an agonistic antibody impairs expansion and survival of CD11b
þ Gr-1 þ cells in vitro and suppresses tumor growth in vivo To test whether cross-linking of CD38 with a monoclonal antibody has an effect on MDSC function(s), MDSCs from spleens of tumor-bearing p120 À/À mice were cultured in methylcellulose-based medium in the presence of an anti-CD38 monoclonal antibody (NIM-R5) or isotype control (IgG2a). Addition of anti-CD38 antibody inhibited growth of colonies from splenic MDSCs, and the effect of anti-CD38 antibody remained unchanged regardless of whether splenocytes were presorted ( Fig. 6A and B) , demonstrating that the anti-CD38 antibody inhibits MDSC proliferation and survival in vitro. In suspension culture, sorted MDSCs survive only a few days, but their survival was further reduced in the presence of anti-CD38 antibody (Fig. 6C) . We also tested whether CD38 cross-linking inhibits accumulation of CD11b within the culture remained consistent (25%-30%; data not shown), these data demonstrate that the CD11b þ Gr-
high population is likely depleted as a result of CD38 cross-linking. Finally, anti-CD38 antibody treatment resulted in decreased tumor growth rate in vivo in a subcutaneous HNM007 transplant ESCC model (Fig. 6E) . In aggregate, these data demonstrate the importance of CD38 for MDSC-mediated ESCC progression and suggest targeting CD38 as an approach to ESCC therapy.
CD38 is expressed on human MDSC-like cell population that is expanded in peripheral blood of advanced-stage cancer patients
To determine whether our findings may be relevant to human cancers, we analyzed CD38 expression in the low-density CD15 hi CD33 lo population of PBMCs from advanced-stage head and neck cancer and non-small cell lung cancer patients and healthy donors. In contrast to our observations in mice, we found that CD38 expression levels were unchanged in CD15 hi CD33 PBMCs from cancer patients, compared with healthy donors (Supplementary Fig. S8 ). However, this population was significantly expanded from 0.5% of total PBMCs in healthy donors to up to 17% in cancer patients (Fig. 7) .
Discussion
Using spontaneous genetic and syngeneic transplant tumor models, as well as an ex vivo differentiation model, we have established for the first time that tumor-derived signals drive expansion of monocytic MDSCs by inducing CD38 expression. Expansion of the CD11b
high cell population occurs after initial splenic MDSC accumulation is evident, which likely indicates a requirement of threshold levels of tumor-derived signals for induction of CD38 by MDSCs (Fig. 5D) . Interestingly, two different ESCC cell lines exhibited differential capacities to induce expansion of CD38 high MDSCs, thereby suggesting that the tumor cells are responsible for promoting CD38 expression on MDSCs. Based upon our ex vivo studies, the tumor-derived signals may act directly on immature myeloid cell populations present in hematopoietic tissues to promote CD38 expression. Furthermore, our data suggest that the tumor-derived signals do not promote enhanced proliferation of CD38 high MDSCs (RB1 pathway was activated in CD38 high MDSCs; Supplementary Fig. S6 ), but provide these cells with increased survival potential. À/À mice produce less tumorassociated microglia in a syngeneic transplant model of glioma (35) . Strikingly, we have found that in Cd38 À/À mice, subcutaneous ESCC tumors induce a less pronounced expansion of MMDSCs, regardless of the cell line used to generate tumors ( Supplementary Fig. S7 ). These findings support the premise that CD38 promotes expansion of M-MDSCs, as well as elevated iNOS expression. We also observed increased NFkB activation in CD11b
high cells. This is consistent with observations made in murine B cells, where CD38 ligation activates NFkB (36) . Furthermore, NFkB-mediated activation of iNOS has been described in LPS-stimulated macrophages (37) , highlighting the possibility that increased NFkB activation in CD38 high MDSCs Figure 6 . (Fig. 5D ). In fact, TNFa inhibition can impair immunosuppressive capacity of MDSCs and induce differentiation in a murine model of chronic inflammation, while MDSCs from Tnf À/-mice have reduced iNOS levels (38) . Our finding of a CXCL16-, IGFBP3-, and IL6-mediated response in MDSCs has not been described previously. However, CXCL16 expression can be promoted by IFNg and TNFa (39), the two most potent inducers of CD38 expression in our ex vivo system. Interestingly, IGFBP3 has been shown to increase intracellular Ca 2þ levels in vitro (40) . Ca 2þ signaling, which can be mediated by ectoenzymatic activity of CD38 (21) , is important for multiple immunomodulatory processes (41, 42) . Therefore, it is possible that in MDSCs IGFBP-3 can be modulating Ca 2þ mobilization by increasing CD38 expression.
IL6 is a major regulator of STAT3 signaling, which is essential for establishment of immunosuppressive microenvironment within the tumor (43) . In MDSCs, STAT3 activation enhances production of the S100A8/A9 proinflammatory proteins, which also contribute to maintenance of a low differentiation or immature state (44) . These data are in agreement with our observation that IL6 can promote CD38 expression on MDSCs generated ex vivo, as CD38 high MDSCs are less differentiated than CD38 low MDSCs (Fig. 4B) . Herein, we demonstrate the efficacy of anti-CD38 monoclonal antibody treatment in vitro and in vivo. Moreover, we report CD38 expression by human MDSCs; therefore, anti-CD38 therapy may represent a novel approach to targeting this immunosuppressive population in cancer treatment strategies. Furthermore, as CD38
high Tregs possess enhanced suppressive potential compared with CD38 low Tregs (18, 19) , anti-CD38 therapy may present the advantage of targeting several immunosuppressive cell types at the same time. Recently, an anti-CD38 monoclonal antibody (daratumumab) was shown to be efficient in treatment of multiple myeloma in preclinical studies (45) . A similar approach may induce ablation of MDSCs in patients with advanced-stage solid cancers, and, thus, may be suitable as an adjuvant to conventional therapies. The expression pattern of CD38 in a broad range of cell types can raise a concern about potential adverse effects of anti-CD38 therapy (46), however, early clinical studies of daratumumab in multiple myeloma have demonstrated an acceptable safety profile, suggesting that an appropriate dosage and treatment schedule allow for minimizing of the effects of targeting CD38 in normal tissue (47) .
MDSCs contribute to the T-cell suppression repertoire found in cancer, which merits further investigation as a prospective therapeutic target (48) . In this study, we have identified CD38 as being suitable for potential MDSC targeting and useful in identification of potently immunosuppressive MDSC populations. Thus, anti-CD38 monoclonal antibody therapy (45) may hold potential for targeting CD38-expressing MDSCs (49) in patients with certain types of cancer.
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